These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

234 related articles for article (PubMed ID: 28262623)

  • 21. 1-year clinical outcomes of diabetic patients treated with everolimus-eluting bioresorbable vascular scaffolds: a pooled analysis of the ABSORB and the SPIRIT trials.
    Muramatsu T; Onuma Y; van Geuns RJ; Chevalier B; Patel TM; Seth A; Diletti R; García-García HM; Dorange CC; Veldhof S; Cheong WF; Ozaki Y; Whitbourn R; Bartorelli A; Stone GW; Abizaid A; Serruys PW; ; ; ; ; ;
    JACC Cardiovasc Interv; 2014 May; 7(5):482-93. PubMed ID: 24746650
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Impact of lesion length and vessel size on clinical outcomes after percutaneous coronary intervention with everolimus- versus paclitaxel-eluting stents pooled analysis from the SPIRIT (Clinical Evaluation of the XIENCE V Everolimus Eluting Coronary Stent System) and COMPARE (Second-generation everolimus-eluting and paclitaxel-eluting stents in real-life practice) Randomized Trials.
    Claessen BE; Smits PC; Kereiakes DJ; Parise H; Fahy M; Kedhi E; Serruys PW; Lansky AJ; Cristea E; Sudhir K; Sood P; Simonton CA; Stone GW
    JACC Cardiovasc Interv; 2011 Nov; 4(11):1209-15. PubMed ID: 22115661
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Magnesium versus poly-L-lactic acid bioresorbable scaffolds: in vivo optical coherence tomography comparison of mechanical performance.
    Abellás-Sequeiros RA; Ocaranza-Sanchez R; Galvaõ-Braga C; Marques J; Gonzalez-Juanatey C
    Arch Cardiol Mex; 2020; 90(1):8-15. PubMed ID: 31996867
    [TBL] [Abstract][Full Text] [Related]  

  • 24. First Report of Edge Vascular Response at 12 Months of Magmaris, A Second-Generation Drug-Eluting Resorbable Magnesium Scaffold, Assessed by Grayscale Intravascular Ultrasound, Virtual Histology, and Optical Coherence Tomography. A Biosolve-II Trial Sub-Study.
    Hideo-Kajita A; Garcia-Garcia HM; Haude M; Joner M; Koolen J; Ince H; Abizaid A; Toelg R; Lemos PA; von Birgelen C; Christiansen EH; Wijns W; Neumann FJ; Kaiser C; Eeckhout E; Teik LS; Escaned J; Azizi V; Kuku KO; Ozaki Y; Dan K; Waksman R
    Cardiovasc Revasc Med; 2019 May; 20(5):392-398. PubMed ID: 31079817
    [TBL] [Abstract][Full Text] [Related]  

  • 25. In vitro mechanical behavior and in vivo healing response of a novel thin-strut ultrahigh molecular weight poly-l-lactic acid sirolimus-eluting bioresorbable coronary scaffold in normal swine.
    Cheng Y; Gasior P; Ramzipoor K; Lee C; McGregor JC; Conditt GB; McAndrew T; Kaluza GL; Granada JF
    Int J Cardiol; 2019 Jul; 286():21-28. PubMed ID: 30967275
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A bioresorbable everolimus-eluting scaffold versus a metallic everolimus-eluting stent for ischaemic heart disease caused by de-novo native coronary artery lesions (ABSORB II): an interim 1-year analysis of clinical and procedural secondary outcomes from a randomised controlled trial.
    Serruys PW; Chevalier B; Dudek D; Cequier A; Carrié D; Iniguez A; Dominici M; van der Schaaf RJ; Haude M; Wasungu L; Veldhof S; Peng L; Staehr P; Grundeken MJ; Ishibashi Y; Garcia-Garcia HM; Onuma Y
    Lancet; 2015 Jan; 385(9962):43-54. PubMed ID: 25230593
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Elutax paclitaxel-eluting balloon followed by bare-metal stent compared with Xience V drug-eluting stent in the treatment of de novo coronary stenosis: a randomized trial.
    Liistro F; Porto I; Angioli P; Grotti S; Ducci K; Falsini G; Bolognese L
    Am Heart J; 2013 Nov; 166(5):920-6. PubMed ID: 24176449
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Comparative Biomechanical Behavior and Healing Profile of a Novel Thinned Wall Ultrahigh Molecular Weight Amorphous Poly-l-Lactic Acid Sirolimus-Eluting Bioresorbable Coronary Scaffold.
    Cheng Y; Gasior P; Xia JG; Ramzipoor K; Lee C; Estrada EA; Dokko D; McGregor JC; Conditt GB; McAndrew T; Kaluza GL; Granada JF
    Circ Cardiovasc Interv; 2017 Jul; 10(7):. PubMed ID: 28701488
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The bioresorbable magnesium scaffold (Magmaris)-State of the art: From basic concept to clinical application.
    Rola P; Włodarczak S; Doroszko A; Lesiak M; Włodarczak A
    Catheter Cardiovasc Interv; 2022 Nov; 100(6):1051-1058. PubMed ID: 36229949
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Bioresorbable drug-eluting magnesium-alloy scaffold: design and feasibility in a porcine coronary model.
    Wittchow E; Adden N; Riedmüller J; Savard C; Waksman R; Braune M
    EuroIntervention; 2013 Apr; 8(12):1441-50. PubMed ID: 23680959
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Magmaris resorbable magnesium scaffold for the treatment of coronary heart disease: overview of its safety and efficacy.
    Bennett J; De Hemptinne Q; McCutcheon K
    Expert Rev Med Devices; 2019 Sep; 16(9):757-769. PubMed ID: 31345074
    [No Abstract]   [Full Text] [Related]  

  • 32. Amsterdam Investigator-initiateD Absorb strategy all-comers trial (AIDA trial): a clinical evaluation comparing the efficacy and performance of ABSORB everolimus-eluting bioresorbable vascular scaffold strategy vs the XIENCE family (XIENCE PRIME or XIENCE Xpedition) everolimus-eluting coronary stent strategy in the treatment of coronary lesions in consecutive all-comers: rationale and study design.
    Woudstra P; Grundeken MJ; Kraak RP; Hassell ME; Arkenbout EK; Baan J; Vis MM; Koch KT; Tijssen JG; Piek JJ; de Winter RJ; Henriques JP; Wykrzykowska JJ
    Am Heart J; 2014 Feb; 167(2):133-40. PubMed ID: 24439973
    [TBL] [Abstract][Full Text] [Related]  

  • 33. One-year head to head comparison of the neointimal response between sirolimus eluting stent with reservoir technology and everolimus eluting stent: an optical coherence tomography study.
    Shiratori Y; Brugaletta S; Alvarez-Contreras L; Azpeitia Y; Ospino N; Gaido S; Delahanty A; Santos A; Martin-Yuste V; Masotti M; Serruys PW; Windecker S; Sabaté M
    Catheter Cardiovasc Interv; 2013 Oct; 82(4):E428-36. PubMed ID: 23441068
    [TBL] [Abstract][Full Text] [Related]  

  • 34. First serial assessment at 6 months and 2 years of the second generation of absorb everolimus-eluting bioresorbable vascular scaffold: a multi-imaging modality study.
    Ormiston JA; Serruys PW; Onuma Y; van Geuns RJ; de Bruyne B; Dudek D; Thuesen L; Smits PC; Chevalier B; McClean D; Koolen J; Windecker S; Whitbourn R; Meredith I; Dorange C; Veldhof S; Hebert KM; Rapoza R; Garcia-Garcia HM
    Circ Cardiovasc Interv; 2012 Oct; 5(5):620-32. PubMed ID: 23048057
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Vasomotor Function Comparative Assessment at 1 and 2 Years Following Implantation of the Absorb Everolimus-Eluting Bioresorbable Vascular Scaffold and the Xience V Everolimus-Eluting Metallic Stent in Porcine Coronary Arteries: Insights From In Vivo Angiography, Ex Vivo Assessment, and Gene Analysis at the Stented/Scaffolded Segments and the Proximal and Distal Edges.
    Gogas BD; Benham JJ; Hsu S; Sheehy A; Lefer DJ; Goodchild TT; Polhemus DJ; Bouchi YH; Hung OY; Yoo SY; Joshi U; Giddens DP; Veneziani A; Quyyumi A; Rapoza R; King SB; Samady H
    JACC Cardiovasc Interv; 2016 Apr; 9(7):728-41. PubMed ID: 27056313
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Five-year clinical and functional multislice computed tomography angiographic results after coronary implantation of the fully resorbable polymeric everolimus-eluting scaffold in patients with de novo coronary artery disease: the ABSORB cohort A trial.
    Onuma Y; Dudek D; Thuesen L; Webster M; Nieman K; Garcia-Garcia HM; Ormiston JA; Serruys PW
    JACC Cardiovasc Interv; 2013 Oct; 6(10):999-1009. PubMed ID: 24156961
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Incidence and short-term clinical outcomes of small side branch occlusion after implantation of an everolimus-eluting bioresorbable vascular scaffold: an interim report of 435 patients in the ABSORB-EXTEND single-arm trial in comparison with an everolimus-eluting metallic stent in the SPIRIT first and II trials.
    Muramatsu T; Onuma Y; García-García HM; Farooq V; Bourantas CV; Morel MA; Li X; Veldhof S; Bartorelli A; Whitbourn R; Abizaid A; Serruys PW;
    JACC Cardiovasc Interv; 2013 Mar; 6(3):247-57. PubMed ID: 23517836
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Complex bifurcation lesions: Randomized comparison of a fully bioresorbable modified t stenting strategy versus bifurcation reconstruction with a dedicated self-expanding stent in combination with bioresorbable scaffolds, an OCT study: Rationale and design of the COBRA II trial.
    Bennett J; Adriaenssens T; Desmet W; Dubois C
    Catheter Cardiovasc Interv; 2016 Nov; 88(6):843-853. PubMed ID: 27184586
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Coronary Artery Healing Process after Bioresorbable Scaffold in Patients with Non-ST-Segment Elevation Myocardial Infarction: Rationale, Design, and Methodology of the HONEST Study.
    Fallesen CO; Maehara A; Antonsen L; Nørregaard Hansen K; Noori M; Flensted Lassen J; Junker A; Hansen HS; Okkels Jensen L
    Cardiology; 2021; 146(2):161-171. PubMed ID: 33524985
    [TBL] [Abstract][Full Text] [Related]  

  • 40. First-in-human evaluation of a novel poly-L-lactide based sirolimus-eluting bioresorbable vascular scaffold for the treatment of de novo native coronary artery lesions: MeRes-1 trial.
    Seth A; Onuma Y; Costa R; Chandra P; Bahl VK; Manjunath CN; Mahajan AU; Kumar V; Goel PK; Wander GS; Kalarickal MS; Kaul U; Kumar VKA; Rath PC; Trehan V; Sengottuvelu G; Mishra S; Abizaid A; Serruys PW
    EuroIntervention; 2017 Jul; 13(4):415-423. PubMed ID: 28504218
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.